Cargando…

Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate

BACKGROUND: To determine the evolution of prostatic multi-parametric magnetic resonance imaging (mp-MRI) signal following transrectal ultrasound (TRUS)-guided biopsy. METHODS: Local ethical permission and informed written consent was obtained from all the participants (n=14, aged 43–69, mean 64 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Latifoltojar, A, Dikaios, N, Ridout, A, Moore, C, Illing, R, Kirkham, A, Taylor, S, Halligan, S, Atkinson, D, Allen, C, Emberton, M, Punwani, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763162/
https://www.ncbi.nlm.nih.gov/pubmed/26195470
http://dx.doi.org/10.1038/pcan.2015.33
_version_ 1782417213416800256
author Latifoltojar, A
Dikaios, N
Ridout, A
Moore, C
Illing, R
Kirkham, A
Taylor, S
Halligan, S
Atkinson, D
Allen, C
Emberton, M
Punwani, S
author_facet Latifoltojar, A
Dikaios, N
Ridout, A
Moore, C
Illing, R
Kirkham, A
Taylor, S
Halligan, S
Atkinson, D
Allen, C
Emberton, M
Punwani, S
author_sort Latifoltojar, A
collection PubMed
description BACKGROUND: To determine the evolution of prostatic multi-parametric magnetic resonance imaging (mp-MRI) signal following transrectal ultrasound (TRUS)-guided biopsy. METHODS: Local ethical permission and informed written consent was obtained from all the participants (n=14, aged 43–69, mean 64 years). Patients with a clinical suspicion of prostate cancer (PSA range 2.2–11.7, mean 6.2) and a negative (PIRAD 1–2/5) pre-biopsy mp-MRI (pre-contrast T1, T2, diffusion-weighted and dynamic-contrast-enhanced MRI) who underwent 10-core TRUS-guided biopsy were recruited for additional mp-MRI examinations performed at 1, 2 and 6 months post biopsy. We quantified mp-MRI peripheral zone (PZ) and transition zone (TZ) normalized T2 signal intensity (nT2-SI); T1 relaxation time (T(10)); diffusion-weighted MRI, apparent diffusion coefficient (ADC); dynamic contrast-enhanced MRI, maximum enhancement (ME); slope of enhancement (SoE) and area-under-the-contrast-enhancement-curve at 120 s (AUC(120)). Significant changes in mp-MRI parameters were identified by analysis of variance with Dunnett's post testing. RESULTS: Diffuse signal changes were observed post-biopsy throughout the PZ. No significant signal change occurred following biopsy within the TZ. Left and right PZ mean nT2-SI (left PZ: 5.73, 5.16, 4.90 and 5.12; right PZ: 5.80, 5.10, 4.84 and 5.05 at pre-biopsy, 1, 2 and 6 months post biopsy, respectively) and mean T(10) (left PZ: 1.02, 0.67, 0.78, 0.85; right PZ: 1.29, 0.64, 0.78, 0.87 at pre-biopsy, 1, 2 and 6 months post biopsy, respectively) were reduced significantly (P<0.05) from pre-biopsy values for up to 6 months post biopsy. Significant changes (P<0.05) of PZ-ME and AUC(120) were observed at 1 month but resolved by 2 months post biopsy. PZ ADC did not change significantly following biopsy (P=0.23–1.0). There was no significant change of any TZ mp-MRI parameter at any time point following biopsy (P=0.1–1.0). CONCLUSIONS: Significant PZ (but not TZ) T2 signal changes persist up to 6 months post biopsy, whereas PZ and TZ ADC is not significantly altered as early as 1 month post biopsy. Caution must be exercised when interpreting T1- and T2-weighted imaging early post biopsy, whereas ADC images are more likely to maintain clinical efficacy.
format Online
Article
Text
id pubmed-4763162
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47631622016-03-07 Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate Latifoltojar, A Dikaios, N Ridout, A Moore, C Illing, R Kirkham, A Taylor, S Halligan, S Atkinson, D Allen, C Emberton, M Punwani, S Prostate Cancer Prostatic Dis Original Article BACKGROUND: To determine the evolution of prostatic multi-parametric magnetic resonance imaging (mp-MRI) signal following transrectal ultrasound (TRUS)-guided biopsy. METHODS: Local ethical permission and informed written consent was obtained from all the participants (n=14, aged 43–69, mean 64 years). Patients with a clinical suspicion of prostate cancer (PSA range 2.2–11.7, mean 6.2) and a negative (PIRAD 1–2/5) pre-biopsy mp-MRI (pre-contrast T1, T2, diffusion-weighted and dynamic-contrast-enhanced MRI) who underwent 10-core TRUS-guided biopsy were recruited for additional mp-MRI examinations performed at 1, 2 and 6 months post biopsy. We quantified mp-MRI peripheral zone (PZ) and transition zone (TZ) normalized T2 signal intensity (nT2-SI); T1 relaxation time (T(10)); diffusion-weighted MRI, apparent diffusion coefficient (ADC); dynamic contrast-enhanced MRI, maximum enhancement (ME); slope of enhancement (SoE) and area-under-the-contrast-enhancement-curve at 120 s (AUC(120)). Significant changes in mp-MRI parameters were identified by analysis of variance with Dunnett's post testing. RESULTS: Diffuse signal changes were observed post-biopsy throughout the PZ. No significant signal change occurred following biopsy within the TZ. Left and right PZ mean nT2-SI (left PZ: 5.73, 5.16, 4.90 and 5.12; right PZ: 5.80, 5.10, 4.84 and 5.05 at pre-biopsy, 1, 2 and 6 months post biopsy, respectively) and mean T(10) (left PZ: 1.02, 0.67, 0.78, 0.85; right PZ: 1.29, 0.64, 0.78, 0.87 at pre-biopsy, 1, 2 and 6 months post biopsy, respectively) were reduced significantly (P<0.05) from pre-biopsy values for up to 6 months post biopsy. Significant changes (P<0.05) of PZ-ME and AUC(120) were observed at 1 month but resolved by 2 months post biopsy. PZ ADC did not change significantly following biopsy (P=0.23–1.0). There was no significant change of any TZ mp-MRI parameter at any time point following biopsy (P=0.1–1.0). CONCLUSIONS: Significant PZ (but not TZ) T2 signal changes persist up to 6 months post biopsy, whereas PZ and TZ ADC is not significantly altered as early as 1 month post biopsy. Caution must be exercised when interpreting T1- and T2-weighted imaging early post biopsy, whereas ADC images are more likely to maintain clinical efficacy. Nature Publishing Group 2015-12 2015-07-21 /pmc/articles/PMC4763162/ /pubmed/26195470 http://dx.doi.org/10.1038/pcan.2015.33 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Latifoltojar, A
Dikaios, N
Ridout, A
Moore, C
Illing, R
Kirkham, A
Taylor, S
Halligan, S
Atkinson, D
Allen, C
Emberton, M
Punwani, S
Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate
title Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate
title_full Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate
title_fullStr Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate
title_full_unstemmed Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate
title_short Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate
title_sort evolution of multi-parametric mri quantitative parameters following transrectal ultrasound-guided biopsy of the prostate
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763162/
https://www.ncbi.nlm.nih.gov/pubmed/26195470
http://dx.doi.org/10.1038/pcan.2015.33
work_keys_str_mv AT latifoltojara evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate
AT dikaiosn evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate
AT ridouta evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate
AT moorec evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate
AT illingr evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate
AT kirkhama evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate
AT taylors evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate
AT halligans evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate
AT atkinsond evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate
AT allenc evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate
AT embertonm evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate
AT punwanis evolutionofmultiparametricmriquantitativeparametersfollowingtransrectalultrasoundguidedbiopsyoftheprostate